Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRIAMINIC-12 vs ACETASOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Temporary relief of nasal congestion,Sinus congestion and pressure,Runny nose,Sneezing,Itchy nose or throat,Allergic rhinitis symptoms
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
Chlorpheniramine: 12-15 hours (terminal) in adults, extended in hepatic impairment or elderly. Pseudoephedrine: 5-8 hours (terminal) in adults with normal renal function, prolonged in renal impairment (up to 20 hours). The combination product's duration is determined by chlorpheniramine.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Pseudoephedrine is partially metabolized in the liver by N-demethylation to norpseudoephedrine, with about 70-90% excreted unchanged in urine. Chlorpheniramine is extensively metabolized in the liver via CYP2D6 and other pathways, including N-demethylation and oxidative deamination.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Triaminic-12 contains chlorpheniramine and pseudoephedrine. Chlorpheniramine: ~50% renal as metabolites, <1% unchanged. Pseudoephedrine: ~70-90% renal unchanged, remainder as metabolites. Total elimination: renal > 90%, fecal < 10%.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Chlorpheniramine: ~70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible binding (<10%).
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
Chlorpheniramine: 3-4 L/kg (widespread distribution, including CNS). Pseudoephedrine: 2-3 L/kg (distributes into body tissues).
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Chlorpheniramine oral: ~25-50% due to first-pass metabolism (extensive hepatic CYP450). Pseudoephedrine oral: ~75-100% well absorbed, minimal first-pass.
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min), reduce frequency to every 24 hours. No adjustment for mild impairment.
No renal adjustment required as systemic absorption is negligible.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, use with caution and consider reducing dose frequency to every 24 hours due to increased half-life.
No hepatic adjustment required as systemic absorption is negligible.
Not recommended for children under 12 years. For children 12 years and older, use adult dosing.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
For patients >65 years: use with caution due to increased risk of anticholinergic effects and potential for hypertension or tachycardia. Consider starting with 1 tablet every 24 hours and monitor response.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
None
None
Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention. May cause dizziness or drowsiness; avoid alcohol and other CNS depressants. Do not exceed recommended dosage. Not for use in children under 12 years.
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Hypersensitivity to any component. Concomitant use with MAO inhibitors or within 2 weeks of discontinuing MAO inhibitors. Severe hypertension or coronary artery disease. Narrow-angle glaucoma. Urinary retention. Use in children under 12 years.
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (contraindicated). Caffeine may increase stimulant effects. Alcohol increases sedation. Grapefruit juice may affect metabolism of pseudoephedrine.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoephedrine is associated with a possible increased risk of gastroschisis in the first trimester; dextromethorphan has limited data but no clear teratogenic signal; chlorpheniramine is considered safe in pregnancy. FDA pregnancy category varies by component: acetaminophen B, pseudoephedrine C, dextromethorphan C, chlorpheniramine B. Overall, avoid in first trimester if possible due to pseudoephedrine.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Acetaminophen is compatible with breastfeeding. Pseudoephedrine passes into breast milk (M/P ratio approximately 3.3) and may reduce milk supply; avoid if possible. Dextromethorphan has limited data but considered low risk. Chlorpheniramine is compatible but may cause drowsiness in infant. Overall, use with caution and monitor infant for sedation.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
No specific dose adjustments recommended for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Pseudoephedrine should be avoided in women with hypertension or preeclampsia.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
Triaminic-12 contains chlorpheniramine (first-generation antihistamine) and pseudoephedrine (decongestant). Avoid use in patients with hypertension, coronary artery disease, or glaucoma. The antihistamine component causes sedation; caution with driving or operating machinery. Onset of action is 30-60 minutes; duration up to 12 hours.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Avoid alcohol and other CNS depressants.,May cause drowsiness; avoid driving until you know how you react.,Do not exceed recommended dose; may cause serious side effects.,Stop and consult doctor if symptoms persist after 7 days or if fever develops.,Do not use if you have high blood pressure, heart disease, or thyroid problems without medical advice.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRIAMINIC-12 vs ACETASOL HC, answered by our medical review team.
TRIAMINIC-12 is a Antihistamine Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.. ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRIAMINIC-12 and ACETASOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRIAMINIC-12 is: Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.. The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRIAMINIC-12 and ACETASOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRIAMINIC-12 is classified as Category C. Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoe. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.